Arbutus Biopharma (ABUS) Competitors $3.14 -0.11 (-3.24%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSAShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors Gemini Therapeutics ImmunityBio Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Arbutus Biopharma (NASDAQ:ABUS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Do analysts recommend ABUS or GMTX? Arbutus Biopharma presently has a consensus target price of $5.50, indicating a potential upside of 74.88%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, ABUS or GMTX? Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.17M97.63-$69.92M-$0.41-7.67Gemini TherapeuticsN/AN/A-$71.87M-$1.00-54.75 Do insiders and institutionals believe in ABUS or GMTX? 43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ABUS or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,196.64%. Gemini Therapeutics' return on equity of -38.78% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-1,196.64% -75.51% -55.81% Gemini Therapeutics N/A -38.78%-35.88% Does the media prefer ABUS or GMTX? In the previous week, Arbutus Biopharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score. Company Overall Sentiment Arbutus Biopharma Neutral Gemini Therapeutics Neutral Which has more risk & volatility, ABUS or GMTX? Arbutus Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. SummaryArbutus Biopharma beats Gemini Therapeutics on 10 of the 14 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$602.36M$2.88B$5.49B$8.96BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-7.6721.1627.5220.15Price / Sales97.63285.45427.69116.17Price / CashN/A41.7026.2128.59Price / Book6.177.407.935.60Net Income-$69.92M-$55.14M$3.17B$248.65M7 Day Performance1.78%4.16%4.76%7.73%1 Month Performance-9.63%0.80%2.87%8.63%1 Year Performance0.80%4.44%35.20%21.67% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma1.4591 of 5 stars$3.14-3.2%$5.50+75.4%+3.7%$600.45M$6.17M-7.6590GMTXGemini TherapeuticsN/A$54.50+0.7%N/A+17.4%$2.36BN/A-54.5030High Trading VolumeIBRXImmunityBio1.8477 of 5 stars$2.64-2.2%$12.25+364.0%-57.5%$2.33B$14.74M-4.55590Negative NewsGap UpTWSTTwist Bioscience4.4624 of 5 stars$36.79+2.4%$50.40+37.0%-21.4%$2.20B$312.97M-11.32990Positive NewsARWRArrowhead Pharmaceuticals3.7854 of 5 stars$15.80-1.7%$43.71+176.7%-34.4%$2.18B$3.55M-11.29400APLSApellis Pharmaceuticals4.4261 of 5 stars$17.31-0.7%$40.05+131.4%-50.4%$2.18B$781.37M-9.67770Analyst RevisionVCELVericel2.8363 of 5 stars$42.55+2.0%$61.14+43.7%-10.5%$2.14B$237.22M1,418.81300Positive NewsRXRXRecursion Pharmaceuticals1.7588 of 5 stars$5.06+0.6%$7.00+38.3%-28.1%$2.06B$58.84M-2.86400NAMSNewAmsterdam Pharma2.2701 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.03B$45.56M-9.634Positive NewsAnalyst UpgradeDNLIDenali Therapeutics4.6337 of 5 stars$13.99-0.8%$33.71+141.0%-30.5%$2.03BN/A-5.24430News CoveragePositive NewsKNSAKiniksa Pharmaceuticals International3.4242 of 5 stars$27.67-1.3%$38.80+40.2%+43.9%$2.02B$423.24M-110.68220Analyst Upgrade Related Companies and Tools Related Companies GMTX Alternatives IBRX Alternatives TWST Alternatives ARWR Alternatives APLS Alternatives VCEL Alternatives RXRX Alternatives NAMS Alternatives DNLI Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
